Decreased sensitivity of 5-HT(1D)
receptors in melancholic depression
by
Whale R, Clifford EM, Bhagwagar Z, Cowen PJ.
University Department of Psychiatry,
Oxford.
Br J Psychiatry 2001 May; 178:454-7

ABSTRACT

BACKGROUND: Brain serotonin (5-HT) function is abnormal in major depression, but the involvement of different 5-HT receptor subtypes has been little studied. The availability of selective ligands now makes it possible to test the sensitivity of 5-HT(1D) receptors in patients with depression. AIMS: The aim of the study was to use the 5-HT(1D) receptor agonist, zolmitriptan, to test the sensitivity of 5-HT(1D) receptors in patients with depression before and after treatment with selective serotonin reuptake inhibitors (SSRIs). METHOD: We measured the growth hormone response to zolmitriptan (5 mg orally) in patients with major depression before and after SSRI treatment. A matched sample of healthy subjects acted as a control group. RESULTS: The growth hormone response to zolmitriptan was blunted in patients with a melancholic depressive syndrome. SSRI treatment produced a marked reduction in zolmitriptan-induced growth hormone release. CONCLUSIONS: Patients with melancholic depression have impaired sensitivity of the post-synaptic 5-HT(1D) receptors that mediate growth hormone release. The reduction in 5-HT(1D) receptor sensitivity following SSRI treatment is probably an adaptive response to increased levels of synaptic 5-HT.

TCAs
SSRIs
5-HT1
5-HT2
5-HT3
5-HT1a
5-HT1b
Eltoprazine
Knockout mice
5-HT2c/5-HT2b
MDMA and 5-HT1a
5-HT1b and reward
5-HT1b and anxiety
Aggression and serotonin
Triptans, migraine and depression

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family